BGD Stock Overview
Develops, produces, and distributes pharmaceutical products in Poland.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Biogened S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł25.40 |
| 52 Week High | zł32.60 |
| 52 Week Low | zł13.60 |
| Beta | 0.73 |
| 11 Month Change | 20.95% |
| 3 Month Change | 28.28% |
| 1 Year Change | 55.83% |
| 33 Year Change | 188.64% |
| 5 Year Change | 193.64% |
| Change since IPO | -36.50% |
Recent News & Updates
A Piece Of The Puzzle Missing From Biogened S.A.'s (WSE:BGD) 25% Share Price Climb
Aug 28
Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)
Aug 22Investors Give Biogened S.A. (WSE:BGD) Shares A 37% Hiding
May 23Recent updates
A Piece Of The Puzzle Missing From Biogened S.A.'s (WSE:BGD) 25% Share Price Climb
Aug 28Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)
Aug 22Investors Give Biogened S.A. (WSE:BGD) Shares A 37% Hiding
May 23Here's Why Biogened (WSE:BGD) Has A Meaningful Debt Burden
May 09Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations
Feb 21Is Biogened (WSE:BGD) A Risky Investment?
Feb 01Biogened S.A. (WSE:BGD) Looks Just Right With A 37% Price Jump
Feb 01We Think Biogened (WSE:BGD) Can Stay On Top Of Its Debt
Jun 30Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly
Oct 08Is Biogened (WSE:BGD) A Risky Investment?
Jun 29Does Biogened (WSE:BGD) Have A Healthy Balance Sheet?
Mar 25These 4 Measures Indicate That Biogened (WSE:BGD) Is Using Debt Reasonably Well
Dec 09Biogened (WSE:BGD) Has A Somewhat Strained Balance Sheet
Jul 29Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly
Apr 30Is Biogened (WSE:BGD) A Risky Investment?
Jan 24Shareholder Returns
| BGD | PL Pharmaceuticals | PL Market | |
|---|---|---|---|
| 7D | 1.6% | -9.9% | -3.5% |
| 1Y | 55.8% | 48.3% | 16.1% |
Return vs Industry: BGD exceeded the Polish Pharmaceuticals industry which returned 48.3% over the past year.
Return vs Market: BGD exceeded the Polish Market which returned 16.1% over the past year.
Price Volatility
| BGD volatility | |
|---|---|
| BGD Average Weekly Movement | 8.7% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in PL Market | 9.5% |
| 10% least volatile stocks in PL Market | 3.3% |
Stable Share Price: BGD's share price has been volatile over the past 3 months.
Volatility Over Time: BGD's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 218 | Andrzej Grzegorzewski | www.biogened.pl |
Biogened S.A. develops, produces, and distributes pharmaceutical products in Poland. The company offers dermo-cosmetics under the Dermedic brand; and thermal water. It also exports its products.
Biogened S.A. Fundamentals Summary
| BGD fundamental statistics | |
|---|---|
| Market cap | zł62.39m |
| Earnings (TTM) | zł5.36m |
| Revenue (TTM) | zł105.76m |
11.6x
P/E Ratio0.6x
P/S RatioIs BGD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BGD income statement (TTM) | |
|---|---|
| Revenue | zł105.76m |
| Cost of Revenue | zł32.88m |
| Gross Profit | zł72.88m |
| Other Expenses | zł67.53m |
| Earnings | zł5.36m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 14, 2024
| Earnings per share (EPS) | 2.18 |
| Gross Margin | 68.91% |
| Net Profit Margin | 5.07% |
| Debt/Equity Ratio | 54.3% |
How did BGD perform over the long term?
See historical performance and comparisonDividends
2.0%
Current Dividend Yield23%
Payout RatioDoes BGD pay a reliable dividends?
See BGD dividend history and benchmarks| Biogened dividend dates | |
|---|---|
| Ex Dividend Date | Sep 12 2024 |
| Dividend Pay Date | Nov 18 2024 |
| Days until Ex dividend | 4 days |
| Days until Dividend pay date | 71 days |
Does BGD pay a reliable dividends?
See BGD dividend history and benchmarks